Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency

DBCOND0091766Adaptive Immunity Anatomical Structures and Fluids

Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as: ADA-SCID · Severe Combined Immunodeficiency Due to ADA Deficiency · Adenosine Deaminase Deficiency - SCID · Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID) · ADA SCID
Classified under: Adaptive Immunity
Anatomical Structures and Fluids
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Immune System Diseases
Immunoglobulins
Pregnancy, Puerperium, and Perinatal Conditions
Indicated drugs: Elapegademase

Resolves to

Vocabularies

MeSHM0525307ICD-10D81.31SNOMED CT22406001UMLSC0392607

What you can answer from here — as of October 23, 2026

1Indicated drugWith each drug's targets and mechanism

Listed above

1Structured indicationPopulation, line of therapy, route and combination as fields, not prose

13Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account